aTyr Pharma Inc., a biotechnology company in the clinical stage, experienced a challenging financial performance in Q3 2024.

The company reported a consolidated net loss of $17.3 million, contributing to a total net loss of $49.1 million for the first nine months of the year.

The increase in operating expenses, particularly in research and development, amounted to approximately $42.1 million, demonstrating the company's ongoing commitment to its long-term clinical programs.

Despite these financial difficulties, aTyr Pharma successfully raised around $21.4 million through its at-the-market offering program during the first nine months of 2024.

This capital is crucial for sustaining operations and advancing clinical trials, including the EFZO-FIT study in collaboration with Kyorin Pharmaceutical Co., Ltd.

The management remains focused on progressing its pipeline of product candidates and exploring additional strategic partnerships and financial support to navigate the current economic landscape.